The PI3K/Akt/mTOR pathway is a central regulator of cell growth, proliferation, survival, and metabolism, and its aberrant activation is a hallmark of many human cancers. Consequently, PI3K inhibitors are a cornerstone of modern oncology drug development. Among these critical compounds, BKM120 (CAS 944396-07-0), also known as Buparlisib or NVP-BKM120, has emerged as a significant tool for researchers seeking to understand and target this pathway.

BKM120 is a potent and selective pan-class I PI3K inhibitor. Its mechanism involves directly targeting the PI3K enzyme, thereby blocking downstream signaling cascades that promote cancer cell survival and proliferation. By inhibiting these processes, BKM120 effectively curbs cell migration and invasion, and crucially, it can induce apoptosis, leading to cancer cell death. This makes it an indispensable reagent for researchers working on novel anticancer agents and combination therapies. If your research demands precise control over PI3K signaling, it is vital to buy PI3K inhibitor BKM120 from a reputable source that guarantees high purity.

The efficacy of BKM120 has been extensively studied in various preclinical cancer models. Studies demonstrate its ability to inhibit tumor growth and sensitize cancer cells to other therapeutic modalities, including chemotherapy and radiotherapy. For scientists aiming to procure Buparlisib for drug discovery, understanding its specific cellular effects is key. As a leading pharmaceutical intermediate manufacturer in China, we provide BKM120 that meets stringent quality standards, ensuring reliable data generation.

Researchers and procurement specialists looking for a dependable CAS 944396-07-0 supplier in China will find our offerings particularly attractive. We are committed to providing high-quality BKM120 at a competitive BKM120 price for research. This allows research institutions and pharmaceutical companies to conduct their vital work without compromising on the quality of their chemical reagents. Partner with us to ensure your cancer research initiatives are supported by top-grade chemical intermediates.